VIR BIOTECHNOLOGY GRANTS NORGINE EXCLUSIVE COMMERCIAL LICENSE TO CHRONIC HEPATITIS DELTA TREATMENT CANDIDATE IN EUROPE, AUSTRALIA & NEW ZEALAND, INCLUDING GLOBAL COST SHARING AGREEMENT FOR ONGOING ECLIPSE CLINICAL DEVELOPMENT PROGRAM

Reuters · 1d ago

Please log in to view news